Bilateral visual field defects in a patient treated with the mek and braf inhibitors trametinib and dabrafenib for melanoma of unknown origin

Discussion: In addition to the widely known class-related retinal toxicity, MEK and BRAF inhibitor-associated adverse events may also involve the optic nerve head, causing visual field defects probably regressing spontaneously after discontinuation of targeted oncologic therapy. In such cases, repeat brain imaging and exclusion of melanoma-associated retinopathy is recommended. Reinitiation of treatment and subsequent dose escalation seem to be feasible, but should be monitored by an ophthalmologist.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research